Aligos Therapeutics, Inc.
ALGS Healthcare Biotechnology
In the quarter to June 2026, revenue grew 2,778.6%, EPS grew 90.9% and free cash flow fell 59.8%, each against the same quarter a year earlier.
Follow ALGS
Aligos Therapeutics, Inc. (ALGS) EV/Sales
As of 16 October 2026, Aligos Therapeutics, Inc. (ALGS) trades at a EV/Sales of 0.6×. Over the past ten years it has ranged from −31.9× (April 2025) to 67.8× (January 2022); the current reading is higher than 81% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 6.5× | (86.61%) |
| FY2024 | 48.8× | — |
| FY2023 | −5.8× | — |
| FY2022 | −6.2× | — |
| FY2021 | 64.8× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 0.9× | (80.02%) |
| Mar 2026 | 4.7× | (27.42%) |
| Dec 2025 | 6.5× | 582.09% |
| Sep 2025 | 1.0× | — |
| 18 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| MGX Metagenomi Therapeutics, Inc. compare | −4.5× |
| ATNM Actinium Pharmaceuticals, Inc. compare | 0.0× |
| IRLA Quince Therapeutics, Inc. compare | n/m |
| BCTX BRIACELL THERAP compare | n/m |
| GNTA Genenta Science S.p.A. Unsponsored ADR compare | n/m |
| NNVC NanoViricides, Inc. compare | n/m |
| LIANY LianBio Sponsored ADR compare | n/m |
| ALGS Aligos Therapeutics, Inc. | 0.6× |
| CRVO CervoMed Inc. compare | 2.7× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)